- Home
- CTSO vs RSF Comparison
CTSO vs RSF Comparison
Compare CTSO & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- RSF
- Stock Information
- Founded
- CTSO 1997
- RSF 2016
- Country
- CTSO United States
- RSF United States
- Employees
- CTSO N/A
- RSF N/A
- Industry
- CTSO Medical/Dental Instruments
- RSF Investment Managers
- Sector
- CTSO Health Care
- RSF Finance
- Exchange
- CTSO Nasdaq
- RSF Nasdaq
- Market Cap
- CTSO 61.3M
- RSF 53.1M
- IPO Year
- CTSO N/A
- RSF N/A
- Fundamental
- Price
- CTSO $1.03
- RSF $15.15
- Analyst Decision
- CTSO Strong Buy
- RSF
- Analyst Count
- CTSO 3
- RSF 0
- Target Price
- CTSO $4.67
- RSF N/A
- AVG Volume (30 Days)
- CTSO 74.6K
- RSF 11.8K
- Earning Date
- CTSO 05-08-2025
- RSF 01-01-0001
- Dividend Yield
- CTSO N/A
- RSF 10.61%
- EPS Growth
- CTSO N/A
- RSF N/A
- EPS
- CTSO N/A
- RSF N/A
- Revenue
- CTSO $35,594,520.00
- RSF N/A
- Revenue This Year
- CTSO $18.72
- RSF N/A
- Revenue Next Year
- CTSO $19.75
- RSF N/A
- P/E Ratio
- CTSO N/A
- RSF N/A
- Revenue Growth
- CTSO 14.51
- RSF N/A
- 52 Week Low
- CTSO $0.70
- RSF $14.81
- 52 Week High
- CTSO $1.61
- RSF $16.23
- Technical
- Relative Strength Index (RSI)
- CTSO 53.19
- RSF 49.16
- Support Level
- CTSO $0.93
- RSF $15.00
- Resistance Level
- CTSO $1.07
- RSF $15.33
- Average True Range (ATR)
- CTSO 0.06
- RSF 0.26
- MACD
- CTSO 0.01
- RSF -0.01
- Stochastic Oscillator
- CTSO 71.43
- RSF 19.35
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.